Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/16/2026, 12:00:00 AM
Eli Lilly is expected to announce Foundayo's heart safety trial results and the FDA's request for additional data on April 16, 2026. Medium impact is estimated based on the clinical significance of obesity treatments expected.
Korean Translation
2026년 4월 16일 파운다요의 심장 안전성 시험 결과 발표 및 FDA의 추가 데이터 요청이 예상됨. 비만 치료제 임상 데이터의 중요성을 고려하여 중간 수준의 영향이 예상됨.
Related Recent Events
Caris Life Sciences Inc (CAI) · Earnings Release
Next quarterly earnings report scheduled.
6/3/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA Q1 FY2027 earnings release and conference call scheduled. Low importance is estimated as a date announcement typically has >=1% price impact.
5/27/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 earnings release and conference call, for which low impact is estimated as the event has not yet occurred, scheduled.
5/11/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is expected to release its Q1 2026 earnings on May 5, 2026. Analysts forecast an EPS of -$0.21 to -$0.30, with the market pricing in a potential post-earnings stock price move of over 15% scheduled.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Q1 2026 financial results and corporate update scheduled.
5/5/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Earnings Release
Q1 2026 earnings release for May 4, 2026, with analysts forecasting EPS of approximately -$0.27 and revenue of $20.73 million; Medium importance reflects expected volatility, and the event is scheduled.
5/4/2026, 12:00:00 AM